Subpoena and CID response counsel, from first notice through resolution.
Federal subpoenas, Civil Investigative Demands (CIDs), HHS-OIG subpoenas, and search warrants each compel documents or testimony under different statutory frameworks. A federal grand jury subpoena under Rule 17 routes the recipient into the criminal investigation pipeline.
A CID under 31 USC § 3733 routes the recipient into the DOJ Civil Division False Claims Act pipeline. An HHS-OIG subpoena under 5 USC § 6 can route to either pipeline. A search warrant under Rule 41 means the criminal investigation is already mature. The first 48 hours after receipt are the most consequential window: document preservation obligations attach immediately, every produced document can become evidence in subsequent civil and criminal proceedings, and the privilege analysis has to be made on a tight clock.
Health Law Alliance defends federal subpoena and CID matters across pharmacies, physicians, healthcare companies, and corporate defendants nationwide. Our former federal prosecutor bench knows what the issuing agency is looking for and what the procedural response should look like.
.png)
Document preservation obligations attach immediately, and any failure (routine destruction, document deletion, lost backups) can produce obstruction exposure on top of the underlying matter. Compelled testimony locks in the witness's account permanently and can become evidence in subsequent civil and criminal proceedings. Material produced in response to one subpoena can be shared across federal agencies and used in parallel investigations. The defense posture has to address all three from the day the subpoena arrives.
Documents produced in response to a federal subpoena, CID, or HHS-OIG subpoena are treated as authenticated business records and become available for use in subsequent civil and criminal proceedings. The materials can be shared between DOJ, HHS-OIG, FBI, DEA, IRS, and state authorities under interagency information-sharing agreements. What is produced cannot be unproduced. A document that supports the defense in one forum may incriminate in another. A privileged document inadvertently produced can produce a subject-matter privilege waiver across all related documents. The pre-production privilege review and the production scope negotiation are the single most consequential procedural decisions in any subpoena response.
A federal grand jury subpoena for testimony, a CID for oral testimony, or an HHS-OIG subpoena for testimony places the witness under oath. The testimony becomes a transcript that follows the witness through every subsequent proceeding. Inconsistent testimony in a later matter can produce false statement (18 USC § 1001) or perjury (18 USC § 1623) exposure separate from the underlying matter. For individuals with potential exposure, the Fifth Amendment privilege against self-incrimination has to be evaluated before the witness appears. For corporate representatives, the corporation generally cannot assert the Fifth Amendment, which makes the witness selection and preparation framework critical.
Material produced in a CID is regularly shared with criminal authorities. Material produced in a grand jury subpoena is regularly shared with the DOJ Civil Division and HHS-OIG. State Medicaid Fraud Control Units share material with federal authorities under interstate compacts. A subpoena response made for one matter often produces material used in a parallel matter the recipient did not know existed. The defense framework has to anticipate the worst-case forum, not just the immediate one. Counsel that handles only one subpoena at a time without the parallel-proceeding analysis regularly produces preventable exposure in matters that surface later.
Federal subpoenas and CIDs operate under specific statutory frameworks with their own privilege rules, their own response procedures, and their own consequences for non-compliance. Defense counsel that treats a federal subpoena like a civil discovery request misreads the procedural posture and the realistic exposure.
Our bench includes a former Assistant U.S. Attorney with DOJ Director's Award recognition and senior healthcare-company counsel. We have defended federal grand jury subpoenas, CIDs from the DOJ Civil Division, HHS-OIG subpoenas, and search warrant matters across pharmacies, physicians, and corporate defendants. This is the protocol.
From the moment of subpoena receipt: issue the litigation hold notice to all custodians who may have responsive material, stop all routine document destruction policies for any potentially responsive document, identify the issuing agency and the line attorney, and contact counsel at the agency to acknowledge receipt and open the dialogue on scope and timing. We evaluate whether the subpoena is a Rule 17 grand jury subpoena, a § 3733 CID, a § 6 HHS-OIG subpoena, or another instrument; whether the recipient is a target (often signaled by a target letter), subject, or witness; and what parallel matters may relate. The first 48 hours produce more leverage on scope than any subsequent procedural step.
Most subpoenas are overbroad as written and can be narrowed through scope negotiation with the issuing attorney. Where negotiation does not produce reasonable scope, motion practice is the alternative: motions to quash or modify under Rule 17(c)(2) (criminal), motions to limit a CID under § 3733(j), and protective orders under Rule 26(c) (civil) preserve the issue for appeal even if denied. The motion forces the issuing attorney to articulate the basis for the demand on the record, which often produces voluntary scope reductions before the court rules. Categorical refusal without a motion is almost never the right move.
The pre-production privilege review is where attorney-client communications, work product, Fifth Amendment material, and joint defense agreement protections are identified and asserted. We negotiate a Federal Rule of Evidence 502(d) clawback order with the issuing attorney before production starts to manage inadvertent production. We document privileged material on a privilege log that supports any subsequent challenge. The production proceeds on a rolling schedule that protects the defense's flexibility on subsequent matters and preserves every available privilege protection.
When the subpoena calls for testimony (grand jury appearance, CID oral testimony, HHS-OIG sworn statement): the witness preparation framework starts weeks before the appearance and runs through the actual testimony. For target witnesses, the Fifth Amendment posture has to be set before the appearance. For subject and corporate-representative witnesses, preparation focuses on the factual record, the privilege limits, and the line of questioning the prosecutor is most likely to pursue. Compelled testimony is permanent; the preparation that goes into it shapes every subsequent civil and criminal proceeding involving the same facts.
Federal subpoenas and CIDs do not arrive at random. The trigger shapes the procedural posture, the realistic exposure, and the parallel-proceeding analysis that should drive the response framework.
Outcomes are summarized for confidentiality. Client names, precise geography, and identifying facts are redacted.
DOJ Declination
Healthcare company received a Civil Investigative Demand from the DOJ Civil Division covering alleged $6M in false claims. Health Law Alliance produced documents under a negotiated rolling schedule, ran a privileged pre-production review of every document before it left the company, presented the factual rebuttal of the government's theory in a meeting with the line attorneys, and prepared a written submission addressing the materiality and falsity defects. DOJ declined both civil intervention and criminal referral. The CID response framework is the most leverage-rich window in any FCA matter.
Physician executive received a federal target letter following a grand jury subpoena to a related entity. Within forty-eight hours of receipt, Health Law Alliance had a privileged read on the exposure, a clear plan for the attorney proffer, and an open dialogue with the line AUSA. The proffer happened three weeks later. Six weeks after that, the AUSA closed the matter without indictment. The defense started before the grand jury voted; the public record of indictment never attached.
Indictment Dismissed
Solo physician faced a multi-count federal indictment under 18 USC § 1347 and § 1349 following an upstream HHS-OIG subpoena and a series of grand jury subpoenas to the practice. Health Law Alliance filed responsive motions, built the procedural record on the materiality and intent issues, and challenged the government's theory through pre-trial motion practice; the indictment collapsed before trial. Federal indictments do not collapse on their own; the procedural record built before trial is what produces dismissal.
Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific matter.
Anthony's background as a former federal prosecutor and executive for major healthcare companies provided a level of expertise and insight that made all the difference. His deep understanding of healthcare law, particularly in litigation and compliance matters, helped navigate complex legal issues with ease.
Seven questions that come up on almost every first call. The answers below are general; specific situations require privileged consultation.
Before you produce documents, before any compelled testimony, before the issuing agency shares material with parallel investigators, have a privileged conversation with attorneys who defend federal subpoenas, CIDs, HHS-OIG subpoenas, and search warrant matters nationwide. Free, confidential, no retainer.
